Radiopharm Theranostics Ltd Cash Flow Conversion Efficiency
Radiopharm Theranostics Ltd cash flow conversion efficiency. Based on the latest financial reports, Radiopharm Theranostics Ltd (RAD) has a cash flow conversion efficiency ratio of -1.349x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-30.11 Million ≈ $-21.31 Million USD) by net assets (AU$22.32 Million ≈ $15.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Radiopharm Theranostics Ltd (2021–2026)
Cash flow conversion efficiency of Radiopharm Theranostics Ltd from 2021 to 2026. This chart illustrates how Radiopharm Theranostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RAD stock price and chart for real-time trading data and today's change.
Radiopharm Theranostics Ltd Cash Flow Conversion Ratio Explained
Radiopharm Theranostics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Radiopharm Theranostics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Radiopharm Theranostics Ltd ranked by their cash flow conversion efficiency. Also see RAD market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kordellos Ch. Bros S.A
AT:KORDE
|
0.075x |
|
Zyrexindo Mandiri Buana PT Tbk
JK:ZYRX
|
0.384x |
|
LDT Inc
KQ:096870
|
0.027x |
|
Nusa Palapa Gemilang PT Tbk
JK:NPGF
|
0.084x |
|
Palatin Technologies, Inc. Common Stock
NASDAQ:PTN
|
-0.417x |
|
HiteJinro Co Ltd
KO:000087
|
0.090x |
|
Quhuo Limited
NASDAQ:QHUOD
|
N/A |
|
Siamraj Public Company Limited
BK:SR
|
0.026x |
Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Ltd (2021–2026)
The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Ltd from 2021 to 2026. Review financial flexibility index of Radiopharm Theranostics Ltd to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | AU$22.32 Million ≈ $15.80 Million |
AU$-52.78 Million ≈ $-37.35 Million |
-2.364x | -176.62% |
| 2025-06-30 | AU$42.87 Million ≈ $30.33 Million |
AU$-36.65 Million ≈ $-25.93 Million |
-0.855x | -1.76% |
| 2024-06-30 | AU$27.35 Million ≈ $19.35 Million |
AU$-22.98 Million ≈ $-16.26 Million |
-0.840x | -65.01% |
| 2023-06-30 | AU$45.58 Million ≈ $32.25 Million |
AU$-23.20 Million ≈ $-16.42 Million |
-0.509x | -223.52% |
| 2022-06-30 | AU$62.96 Million ≈ $44.55 Million |
AU$-9.91 Million ≈ $-7.01 Million |
-0.157x | -159.62% |
| 2021-06-30 | AU$-124.70K ≈ $-88.24K |
AU$-32.91K ≈ $-23.29K |
0.264x | -- |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeuti… Read more